OraSure Technologies Announces Director Retirement
24 2월 2017 - 8:00PM
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care
diagnostic tests and specimen collection devices, today announced
that Roger L. Pringle will be retiring as a member of the Company’s
Board of Directors, effective May 16, 2017. Mr. Pringle is
the Company’s longest tenured Director, having served on the Board
since September 2000. Prior to that, Mr. Pringle served as
Chairman of the Board and Director of one of the Company’s
predecessors, Epitope, Inc. Mr. Pringle has also served as a
member of both the Compensation and Audit Committees and previously
as Chairman of the Compensation Committee.
“On behalf of the Company and my fellow
Directors, I would like to express my deepest appreciation to Roger
for his dedicated service to the Company and the Board of
Directors,” said Dr. Stephen Tang, Chairman of OraSure’s Board of
Directors. “During Roger’s tenure, there have been many
significant changes at OraSure and the Company has grown
substantially. His steadfast commitment and leadership have
contributed to our success over these many years. Roger will
be greatly missed and we wish him and his family nothing but good
health and success for the future.”
About OraSure Technologies
OraSure Technologies is a leader in the
development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
Company contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
www.orasure.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024